Using mutant KRAS as the trigger, not just the target, for payload release
- This viewpoint proposes covalent-induced drug conjugates, where mutant KRAS is both the target and the switch that releases the drug.
- Recognition of KRAS G12C is coupled to intracellular release of potent tubulin inhibitors.
- The idea is to turn oncogene engagement into localized cytotoxicity while limiting systemic exposure to the payload.
💡 Points Based on the abstract
A covalent trigger is consumed one-to-one, so payload release is capped by how much KRAS G12C a cell expresses, and approved inhibitors already compete for the same pocket. The idea lives or dies on cleavage chemistry and on whether tubulin payload leaks in normal cells; a viewpoint offers no data on either.
📄 Paper · ACS Medicinal Chemistry Letters ↗ Turning KRAS into a Molecular Trigger: Covalent-Induced Drug Conjugates for Conditional Tubulin Poisoning